Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

NCT05371496 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Cardiomyopathy
Heart Failure With Preserved Ejection Fraction (HFpEF)
Obesity

Interventions

DRUG: Semaglutide
DRUG: Placebo
BEHAVIORAL: Counselling on healthy lifestyle intervention

Sponsor

Mayo Clinic

Collaborators

[object Object]